Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C44Mab-108) using Enzyme-Linked Immunosorbent Assay

Version 1 : Received: 3 November 2023 / Approved: 3 November 2023 / Online: 3 November 2023 (06:38:38 CET)

A peer-reviewed article of this Preprint also exists.

Suzuki, H., Tawara, M., Hirayama, A., Goto, N., Tanaka, T., Kaneko, M. K., & Kato, Y. (2024). Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C44Mab-108) Using Enzyme-Linked Immunosorbent Assay. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. Suzuki, H., Tawara, M., Hirayama, A., Goto, N., Tanaka, T., Kaneko, M. K., & Kato, Y. (2024). Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C44Mab-108) Using Enzyme-Linked Immunosorbent Assay. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy.

Abstract

CD44 is a type I transmembrane glycoprotein, and possesses various isoforms which are largely classified into CD44 standard and CD44 variant (CD44v) isoforms. Some variant-encoded regions play critical roles in tumor progression. However, the function of CD44 variant 4 (CD44v4)-encoded region has not been fully understood. Using peptide immunization, we developed an anti-CD44v4 mAb, C44Mab-108, which is useful for flow cytometry, western blotting, and immunohistochemistry. In this study, we determined the critical epitope of C44Mab-108 by enzyme-linked immunosorbent assay (ELISA). We used the alanine (or glycine)-substituted peptides of the CD44v4-encoded region (amino acids 271-290 of human CD44v3-10), and found that C44Mab-108 did not recognize the alanine-substituted peptides of D280A and W281A. Furthermore, these peptides could not inhibit the recognition of C44Mab-108 in flow cytometry and immunohistochemistry. The results indicate that the critical binding epitope of C44Mab-108 includes Asp280 and Trp281 of CD44v3-10.

Keywords

CD44; CD44 variant 4; monoclonal antibody; epitope; enzyme-linked immunosorbent assay

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.